Clinical characteristics, treatment, and long-term outcome of patients with brain metastases from thyroid cancer DOI Creative Commons
Ladislaia Wolff, Ariane Steindl, Petar Popov

et al.

Clinical & Experimental Metastasis, Journal Year: 2023, Volume and Issue: 40(3), P. 217 - 226

Published: May 23, 2023

Brain metastases (BM) in patients with thyroid cancer (TC) are rare an incidence of 1% for papillary and follicular, 3% medullary up to 10% anaplastic TC (PTC, FTC, MTC ATC). Little is known about the characteristics management BM from TC. Thus, we retrospectively analyzed histologically verified radiologically identified Vienna Metastasis Registry. A total 20/6074 included database since 1986 had 13/20 were female. Ten 8 PTC, one ATC. The median age at diagnosis was 68 years. All but symptomatic a singular BM. Synchronous primary found 6 patients, while time 13 years PTC (range 1.9-24), 4 FTC 2.1-41) 22 patient. overall survival months 1.8-57), 26 3.9-188), 12 3 ATC In conclusion, development exceedingly most common presentation single lesion. While generally constitute poor prognostic factor, individual experience long-term following local therapy.

Language: Английский

A comprehensive analysis and comparative study of the trends in thyroid cancer burden in China and globally from 1990 to 2021, with projections for the next 15 Years DOI Creative Commons
Yulai Yin,

Xiaoyu Zhang

Frontiers in Oncology, Journal Year: 2025, Volume and Issue: 15

Published: Feb. 7, 2025

This study aims to analyze the trends in incidence, prevalence, mortality, and disability-adjusted life years (DALYs) of thyroid cancer across gender age groups China globally from 1990 2021, using data Global Burden Disease (GBD) database. Additionally, it projects burden for next 15 both global population. Thyroid cancer-related were extracted 2021 GBD dataset. The average annual percentage change (AAPC) corresponding 95% confidence intervals (95% CI) calculated Joinpoint regression reflect burden. R software was used perform a gender- age-specific analysis visualize Furthermore, Autoregressive Integrated Moving Average (ARIMA) model employed project over years. results indicate rising trend incidence prevalence globally. Conversely, mortality rate DALYs show declining same period. Age-specific revealed that is most prevalent among individuals aged 50-64. Gender-specific indicated higher females than males. Projections age-standardized rates males are expected continue While projected decline significantly, predicted stabilize. Between number cases has increased globally, while shown marked decline. persist growing population affected by reflects substantial disease burden, making significant public health concern. formulation proactive effective policies urgently needed.

Language: Английский

Citations

0
Circulating Biomarkers of Thyroid Cancer: An Appraisal DOI Open Access
Marta Codrich,

Alessia Biasotto,

Federica DˈAurizio

et al.

Journal of Clinical Medicine, Journal Year: 2025, Volume and Issue: 14(5), P. 1582 - 1582

Published: Feb. 26, 2025

Thyroid cancer is the most prevalent endocrine cancer. The prognosis depends on type and stage at diagnosis. treatments involve surgery, possibly followed by additional therapeutic options such as hormone therapy, radiation targeted therapy chemotherapy. Besides well-known thyroid tumor biomarkers, new circulating biomarkers are now emerging. Advances in genomic, transcriptomic proteomic technologies have allowed development of novel biomarkers. This review explores current literature data to critically analyze benefits limitations routinely measured for diagnosis monitoring also sheds light focusing challenges their use clinical management cancer, underlining need identification a generation

Language: Английский

Citations

0
Regulated cell death in thyroid follicular cells: Molecular insights into pyroptosis, apoptosis, and necrosis DOI

Honghao He,

Daiwei Zhao

Gene Reports, Journal Year: 2025, Volume and Issue: unknown, P. 102185 - 102185

Published: March 1, 2025

Language: Английский

Citations

0
Molecular oncology of iodine refractory thyroid cancer current therapies and perspective DOI
François Cherifi, Ahmad Awada

Critical Reviews in Oncology/Hematology, Journal Year: 2025, Volume and Issue: unknown, P. 104679 - 104679

Published: March 1, 2025

Language: Английский

Citations

0
Refining NTRK Fusion Detection in Papillary Thyroid Carcinoma Through Pan-TRK Immunohistochemistry and Histopathologic Features DOI
Hyun Lee,

Sue Youn Kim,

Ji Min Park

et al.

Endocrine Pathology, Journal Year: 2025, Volume and Issue: 36(1)

Published: March 18, 2025

Language: Английский

Citations

0
PIS as a regulator of cellular heterogeneity, prognostic significance, and immune landscape in thyroid cancer DOI
Xianjiang Wu, Lei Dai, Weidong Zhang

et al.

Translational Oncology, Journal Year: 2025, Volume and Issue: 55, P. 102296 - 102296

Published: March 25, 2025

Language: Английский

Citations

0
High-Grade Non-Anaplastic Thyroid Carcinomas of Follicular Cell Origin: A Review of Poorly Differentiated and High-Grade Differentiated Carcinomas DOI
Vincent Cracolici, Nicole A. Cipriani

Endocrine Pathology, Journal Year: 2023, Volume and Issue: 34(1), P. 34 - 47

Published: Jan. 24, 2023

Language: Английский

Citations

9
Characterization of the Thyroid Cancer Genomic Landscape by Plasma-Based Circulating Tumor DNA Next-Generation Sequencing DOI
Valentina Tarasova,

Jill Tsai,

Jude Masannat

et al.

Thyroid, Journal Year: 2023, Volume and Issue: 34(2), P. 197 - 205

Published: Nov. 14, 2023

Background: The limited availability of targeted therapies in thyroid cancer (TC) has challenged conventional treatment algorithms and established urgency for the identification targetable genomic abnormalities. In addition to widely adopted tissue-based next-generation sequencing (NGS), plasma-based circulating tumor DNA (ctDNA) NGS is rapidly emerging as a biomarker detection method steadily gaining utility across solid tumors. To date, alterations TC have not been determined. Herein, we profile potential actionable mutations detected through ctDNA patients with subtypes. Methods: A retrospective data analysis Guardant Health, Inc. database was performed using commercially available Guardant360® plasma-NGS test on samples from adult collected between 2016 2021. landscape blood mutation burden (bTMB) were analyzed different types TC: anaplastic (ATC), papillary (PTC), follicular (FTC), oncolytic carcinoma (OCA), poorly differentiated (PDTC), medullary (MTC), otherwise specified (TC NOS). Results: Of 1094 included most n = 876 had NOS, 20% specific diagnosis (92 ATC, 62 PTC, 14 FTC, 16 OCA, 2 PDTC, 32 MTC patients). median age 65 (range 10–98) 47.3% male. 78.3% one or more alteration by NGS. TP53 (46.9%) common among all TC. BRAFV600E 27.2% 35.7% none FTC. RAS 18.5% 11.9% 62.5% RET, ALK, NTRK fusions seen 1.1%, 0.5%, 0.2% TC, respectively. RET 66.7% MTC. bTMB 159 patients. mean higher ATC compared other (p 0.0011, 0.0557, <0.0001, respectively). Conclusions: Plasma-based comprehensive promising TC; however, future validation clinical paired plasma needed.

Language: Английский

Citations

9
Clinicopathological analysis of thyroid carcinomas with the RET and NTRK fusion genes: characterization for genetic analysis DOI Creative Commons
Yoichiro Okubo, Soji Toda, Mei Kadoya

et al.

Virchows Archiv, Journal Year: 2024, Volume and Issue: 485(3), P. 509 - 518

Published: March 12, 2024

Thyroid carcinomas exhibit various genetic alterations, including the RET and NTRK fusion genes that are targets for molecular therapies. Thus, detecting is crucial devising effective treatment plans. This study characterized pathological findings associated with these to identify specimens suitable analysis. carcinoma cases positive were analyzed using Oncomine Dx Target Test. Clinicopathological data collected assessed. Among 74 patients tested, 8 had 1 NTRK3 gene. Specifically, of gene cases, 6 exhibited "BRAF-like" atypia 2 showed "RAS-like" atypia, while single case an presented atypia. Apart from one poorly differentiated thyroid carcinoma, most involved papillary (PTCs). Primary tumors varied structural patterns a high proportion non-papillary structures. Dysmorphic clear cells frequently observed. BRAF V600E immunoreactivity was negative in all cases. Interestingly, some similarities diffuse sclerosing variant PTC characteristics. While calcification lymph node metastases mild, primary typically required hydrochloric acid-based decalcification tissue preparation. highlights benefits combining morphological immunohistochemical analyses detection posits more analysis owing their mild calcification. Our results emphasize importance accurate sample processing diagnosing treating carcinomas.

Language: Английский

Citations

3
Supramolecular nanofibers co-loaded with dabrafenib and doxorubicin for targeted and synergistic therapy of differentiated thyroid carcinoma DOI Creative Commons
Peng Chen,

Xiaoyao Cai,

Ganen Mu

et al.

Theranostics, Journal Year: 2023, Volume and Issue: 13(7), P. 2140 - 2153

Published: Jan. 1, 2023

Rationale: Although surgery, radioiodine therapy, and thyroid hormone therapy are the primary clinical treatments for differentiated carcinoma (DTC), effective locally advanced or progressive DTC remains challenging.BRAF V600E, most common BRAF mutation subtype, is highly related to DTC.Previous studies prove that combination of kinase inhibitors chemotherapeutic drugs may be a potential approach treatment.In this study, supramolecular peptide nanofiber (SPNs) co-loaded with dabrafenib (Da) doxorubicin (Dox) was constructed targeted synergistic V600E + DTC.Methods: A self-assembling (Biotin-G D F YGRGD, termed SPNs) bearing biotin at N-terminus cancer-targeting ligand RGD C-terminus used as carrier co-loading Da Dox.D-phenylalanine D-tyrosine ( Y) improve stability peptides in vivo.Under multiple non-covalent interactions, SPNs/Da/Dox assembled into longer denser nanofibers.RGD endows self-assembled nanofibers targeting cancer cells co-delivery, thereby improving cellular uptake payloads.Results: Both Dox indicated decreased IC50 values upon encapsulation SPNs.Co-delivery by SPNs exhibited strongest therapeutic effect vitro vivo inhibiting ERK phosphorylation mutant cells.Moreover, enable efficient drug delivery lower dosage, significantly reducing its side effects. Conclusion:This study proposes promising paradigm treatment using carriers.

Language: Английский

Citations

9